RT Journal Article
SR Electronic
T1 Alteration of Cell Surface Markers CD38 and CD138 in Lymphoproliferative Disorders in the Ocular Adnexa
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2019
OP 2023
DO 10.21873/anticanres.14158
VO 40
IS 4
A1 SUIMON, YUKA
A1 KASE, SATORU
A1 MIURA, ICHIRO
A1 ISHIJIMA, KAN
A1 ISHIDA, SUSUMU
YR 2020
UL http://ar.iiarjournals.org/content/40/4/2019.abstract
AB Background/Aim: CD38 is a cell surface marker commonly present in plasma cells and activated T cells, while CD138 is a representative plasma cell marker. The aim of this study was to describe the expression of cell surface markers including CD38 and CD138, in the tumors of patients with IgG4-related ophthalmic disease (IgG4-ROD) and extranodal marginal zone B-cell lymphoma (EMZL) of the ocular adnexa. Materials and Methods: Twenty-four consecutive patients of whom 12 had IgG4-ROD and 12 EMZL were enrolled in this study. Medical records were reviewed for flow cytometry (FCM) results on conventional T-cell markers, B-cell markers, CD38 and CD138. Results: Positive rates of T-cell markers, CD38 and CD138 were significantly higher in IgG4-ROD than in EMZL (p<0.01 and p<0.05, respectively). Conclusion: Our FCM results on CD38 and CD138 showed that the lymphocyte populations were different between IgG4-ROD and EMZL, which may reflect the different pathophysiology of the two diseases.